- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Chemotherapy Induced Peripheral Neuropathy Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Chemotherapy Induced Peripheral Neuropathy Treatment market size is estimated to be worth US$ 1723.6 million in 2021 and is forecast to a readjusted size of USD 2613.1 million by 2028 with a CAGR of 6.1% during review period. Platinum Agents accounting for % of the Chemotherapy Induced Peripheral Neuropathy Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Calcium Channel α2-delta Ligands segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment include Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, and Metys Pharmaceuticals AG, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Chemotherapy Induced Peripheral Neuropathy Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Market segment by Application can be divided into
Platinum Agents
Taxanes
Vinca Alkaloids
Others
The key market players for global Chemotherapy Induced Peripheral Neuropathy Treatment market are listed below:
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Chemotherapy Induced Peripheral Neuropathy Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, with price, sales, revenue and global market share of Chemotherapy Induced Peripheral Neuropathy Treatment from 2019 to 2022.
Chapter 3, the Chemotherapy Induced Peripheral Neuropathy Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Chemotherapy Induced Peripheral Neuropathy Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Chemotherapy Induced Peripheral Neuropathy Treatment market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Chemotherapy Induced Peripheral Neuropathy Treatment.
Chapter 13, 14, and 15, to describe Chemotherapy Induced Peripheral Neuropathy Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Calcium Channel α2-delta Ligands
1.2.3 Antidepressants
1.2.4 Opioids
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Platinum Agents
1.3.3 Taxanes
1.3.4 Vinca Alkaloids
1.3.5 Others
1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size & Forecast
1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume (2017-2028)
1.4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (2017-2028)
1.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity Analysis
1.5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Total Production Capacity (2017-2028)
1.5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
1.6.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
1.6.3 Chemotherapy Induced Peripheral Neuropathy Treatment Trends Analysis
2 Manufacturers Profiles
2.1 Aptinyx Inc
2.1.1 Aptinyx Inc Details
2.1.2 Aptinyx Inc Major Business
2.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Asahi Kasei Pharma Corp
2.2.1 Asahi Kasei Pharma Corp Details
2.2.2 Asahi Kasei Pharma Corp Major Business
2.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Regenacy Pharmaceuticals
2.3.1 Regenacy Pharmaceuticals Details
2.3.2 Regenacy Pharmaceuticals Major Business
2.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 MAKScientific LLC
2.4.1 MAKScientific LLC Details
2.4.2 MAKScientific LLC Major Business
2.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Metys Pharmaceuticals AG
2.5.1 Metys Pharmaceuticals AG Details
2.5.2 Metys Pharmaceuticals AG Major Business
2.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Nemus Bioscience Inc
2.6.1 Nemus Bioscience Inc Details
2.6.2 Nemus Bioscience Inc Major Business
2.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 PledPharma
2.7.1 PledPharma Details
2.7.2 PledPharma Major Business
2.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Sova Pharmaceuticals Inc
2.8.1 Sova Pharmaceuticals Inc Details
2.8.2 Sova Pharmaceuticals Inc Major Business
2.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 DermaXon LLC
2.9.1 DermaXon LLC Details
2.9.2 DermaXon LLC Major Business
2.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Kineta Inc
2.10.1 Kineta Inc Details
2.10.2 Kineta Inc Major Business
2.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Krenitsky Pharmaceuticals Inc
2.11.1 Krenitsky Pharmaceuticals Inc Details
2.11.2 Krenitsky Pharmaceuticals Inc Major Business
2.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 PeriphaGen
2.12.1 PeriphaGen Details
2.12.2 PeriphaGen Major Business
2.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Apexian Pharma
2.13.1 Apexian Pharma Details
2.13.2 Apexian Pharma Major Business
2.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 WinSanTor
2.14.1 WinSanTor Details
2.14.2 WinSanTor Major Business
2.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
2.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Chemotherapy Induced Peripheral Neuropathy Treatment Breakdown Data by Manufacturer
3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Chemotherapy Induced Peripheral Neuropathy Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturer Market Share in 2021
3.4.2 Top 6 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturer Market Share in 2021
3.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Chemotherapy Induced Peripheral Neuropathy Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region
4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Region (2017-2028)
4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2017-2028)
4.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2017-2028)
4.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2017-2028)
4.4 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2017-2028)
4.5 South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2017-2028)
4.6 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Type (2017-2028)
5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2017-2028)
5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Application (2017-2028)
6.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2017-2028)
6.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2017-2028)
7.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2028)
7.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
7.3.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Country (2017-2028)
7.3.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2017-2028)
8.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2028)
8.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
8.3.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Country (2017-2028)
8.3.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2017-2028)
9.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2028)
9.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region
9.3.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2017-2028)
10.2 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2028)
10.3 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
10.3.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Country (2017-2028)
10.3.2 South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2017-2028)
11.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2028)
11.3 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
11.3.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Chemotherapy Induced Peripheral Neuropathy Treatment and Key Manufacturers
12.2 Manufacturing Costs Percentage of Chemotherapy Induced Peripheral Neuropathy Treatment
12.3 Chemotherapy Induced Peripheral Neuropathy Treatment Production Process
12.4 Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Chemotherapy Induced Peripheral Neuropathy Treatment Typical Distributors
13.3 Chemotherapy Induced Peripheral Neuropathy Treatment Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Aptinyx Inc Basic Information, Manufacturing Base and Competitors
Table 4. Aptinyx Inc Major Business
Table 5. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 6. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Asahi Kasei Pharma Corp Basic Information, Manufacturing Base and Competitors
Table 8. Asahi Kasei Pharma Corp Major Business
Table 9. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 10. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Regenacy Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 12. Regenacy Pharmaceuticals Major Business
Table 13. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 14. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. MAKScientific LLC Basic Information, Manufacturing Base and Competitors
Table 16. MAKScientific LLC Major Business
Table 17. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 18. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Metys Pharmaceuticals AG Basic Information, Manufacturing Base and Competitors
Table 20. Metys Pharmaceuticals AG Major Business
Table 21. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 22. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Nemus Bioscience Inc Basic Information, Manufacturing Base and Competitors
Table 24. Nemus Bioscience Inc Major Business
Table 25. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 26. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. PledPharma Basic Information, Manufacturing Base and Competitors
Table 28. PledPharma Major Business
Table 29. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 30. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Sova Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 32. Sova Pharmaceuticals Inc Major Business
Table 33. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 34. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. DermaXon LLC Basic Information, Manufacturing Base and Competitors
Table 36. DermaXon LLC Major Business
Table 37. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 38. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Kineta Inc Basic Information, Manufacturing Base and Competitors
Table 40. Kineta Inc Major Business
Table 41. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 42. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Krenitsky Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 44. Krenitsky Pharmaceuticals Inc Major Business
Table 45. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 46. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. PeriphaGen Basic Information, Manufacturing Base and Competitors
Table 48. PeriphaGen Major Business
Table 49. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 50. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Apexian Pharma Basic Information, Manufacturing Base and Competitors
Table 52. Apexian Pharma Major Business
Table 53. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 54. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. WinSanTor Basic Information, Manufacturing Base and Competitors
Table 56. WinSanTor Major Business
Table 57. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product and Services
Table 58. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 59. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 60. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 61. Market Position of Manufacturers in Chemotherapy Induced Peripheral Neuropathy Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 62. Global Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity by Company, (K Units): 2020 VS 2021
Table 63. Head Office and Chemotherapy Induced Peripheral Neuropathy Treatment Production Site of Key Manufacturer
Table 64. Chemotherapy Induced Peripheral Neuropathy Treatment New Entrant and Capacity Expansion Plans
Table 65. Chemotherapy Induced Peripheral Neuropathy Treatment Mergers & Acquisitions in the Past Five Years
Table 66. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2017-2022) & (K Units)
Table 67. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2023-2028) & (K Units)
Table 68. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2017-2022) & (USD Million)
Table 69. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2023-2028) & (USD Million)
Table 70. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2017-2022) & (K Units)
Table 71. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2023-2028) & (K Units)
Table 72. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2017-2022) & (USD Million)
Table 73. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2023-2028) & (USD Million)
Table 74. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2017-2022) & (US$/Unit)
Table 75. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2023-2028) & (US$/Unit)
Table 76. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2022) & (K Units)
Table 77. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2023-2028) & (K Units)
Table 78. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2017-2022) & (USD Million)
Table 79. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2023-2028) & (USD Million)
Table 80. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2017-2022) & (US$/Unit)
Table 81. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2023-2028) & (US$/Unit)
Table 82. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2017-2022) & (K Units)
Table 83. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2023-2028) & (K Units)
Table 84. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2017-2022) & (USD Million)
Table 85. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2023-2028) & (USD Million)
Table 86. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2017-2022) & (K Units)
Table 87. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2023-2028) & (K Units)
Table 88. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2022) & (K Units)
Table 89. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2023-2028) & (K Units)
Table 90. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2017-2022) & (K Units)
Table 91. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2023-2028) & (K Units)
Table 92. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2017-2022) & (USD Million)
Table 93. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2023-2028) & (USD Million)
Table 94. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2017-2022) & (K Units)
Table 95. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2023-2028) & (K Units)
Table 96. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2022) & (K Units)
Table 97. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2023-2028) & (K Units)
Table 98. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2017-2022) & (K Units)
Table 99. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2023-2028) & (K Units)
Table 100. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2017-2022) & (USD Million)
Table 101. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2023-2028) & (USD Million)
Table 102. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2017-2022) & (K Units)
Table 103. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2023-2028) & (K Units)
Table 104. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2022) & (K Units)
Table 105. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2023-2028) & (K Units)
Table 106. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2017-2022) & (K Units)
Table 107. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2023-2028) & (K Units)
Table 108. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2017-2022) & (USD Million)
Table 109. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2023-2028) & (USD Million)
Table 110. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2017-2022) & (K Units)
Table 111. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2023-2028) & (K Units)
Table 112. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2022) & (K Units)
Table 113. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2023-2028) & (K Units)
Table 114. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2017-2022) & (K Units)
Table 115. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2023-2028) & (K Units)
Table 116. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2017-2022) & (USD Million)
Table 117. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2023-2028) & (USD Million)
Table 118. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2017-2022) & (K Units)
Table 119. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2023-2028) & (K Units)
Table 120. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2017-2022) & (K Units)
Table 121. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2023-2028) & (K Units)
Table 122. Chemotherapy Induced Peripheral Neuropathy Treatment Raw Material
Table 123. Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment Raw Materials
Table 124. Direct Channel Pros & Cons
Table 125. Indirect Channel Pros & Cons
Table 126. Chemotherapy Induced Peripheral Neuropathy Treatment Typical Distributors
Table 127. Chemotherapy Induced Peripheral Neuropathy Treatment Typical Customers
List of Figures
Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Picture
Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type in 2021
Figure 3. Calcium Channel α2-delta Ligands
Figure 4. Antidepressants
Figure 5. Opioids
Figure 6. Others
Figure 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application in 2021
Figure 8. Platinum Agents
Figure 9. Taxanes
Figure 10. Vinca Alkaloids
Figure 11. Others
Figure 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (2017-2028) & (K Units)
Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (2017-2028) & (US$/Unit)
Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity (2017-2028) & (K Units)
Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity by Geographic Region: 2022 VS 2028
Figure 18. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
Figure 19. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
Figure 20. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
Figure 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturer in 2021
Figure 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Manufacturer in 2021
Figure 23. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 24. Top 3 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturer (Revenue) Market Share in 2021
Figure 25. Top 6 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturer (Revenue) Market Share in 2021
Figure 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2017-2028)
Figure 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2017-2028)
Figure 28. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2017-2028) & (USD Million)
Figure 29. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2017-2028) & (USD Million)
Figure 30. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2017-2028) & (USD Million)
Figure 31. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2017-2028) & (USD Million)
Figure 32. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2017-2028) & (USD Million)
Figure 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2017-2028)
Figure 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2017-2028)
Figure 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2017-2028) & (US$/Unit)
Figure 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2017-2028)
Figure 37. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2017-2028)
Figure 38. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2017-2028) & (US$/Unit)
Figure 39. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2017-2028)
Figure 40. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2017-2028)
Figure 41. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2017-2028)
Figure 42. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2017-2028)
Figure 43. United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2017-2028)
Figure 47. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2017-2028)
Figure 48. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2017-2028)
Figure 49. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2017-2028)
Figure 50. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2017-2028)
Figure 58. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2017-2028)
Figure 59. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2017-2028)
Figure 66. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2017-2028)
Figure 67. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2017-2028)
Figure 68. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2017-2028)
Figure 69. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2017-2028)
Figure 72. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2017-2028)
Figure 73. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2017-2028)
Figure 74. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2017-2028)
Figure 75. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. South Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Manufacturing Cost Structure Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment in 2021
Figure 80. Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 81. Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
Figure 83. Methodology
Figure 84. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
